Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

被引:0
|
作者
Makiko Ono
Hitoshi Tsuda
Chikako Shimizu
Sohei Yamamoto
Tatsuhiro Shibata
Harukaze Yamamoto
Taizo Hirata
Kan Yonemori
Masashi Ando
Kenji Tamura
Noriyuki Katsumata
Takayuki Kinoshita
Yuichi Takiguchi
Hideki Tanzawa
Yasuhiro Fujiwara
机构
[1] National Cancer Center Hospital,Breast and Medical Oncology Division
[2] National Cancer Center Hospital,Clinical Laboratory Division, Department of Pathology
[3] National Defense Medical College,Department of Basic Pathology
[4] Center for Medical Genomics,Cancer Genomics Project, Pathology Division
[5] National Cancer,Breast Surgery Division
[6] Center Research Institute,Department of Respirology
[7] National Cancer Center Hospital,Department of Clinical Molecular Biology
[8] Graduate School of Medicine,undefined
[9] Chiba University,undefined
[10] Graduate School of Medicine,undefined
[11] Chiba University,undefined
来源
关键词
Triple-negative breast cancer; Neoadjuvant chemotherapy; Pathological complete response; Tumor-infiltrating lymphocytes; Tumor cell apoptosis;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of the present study was to identify histological surrogate predictive markers of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC). Among 474 patients who received NAC and subsequent surgical therapy for stage II–III invasive breast carcinoma between 1999 and 2007, 102 (22%) had TNBC, and 92 core needle biopsy (CNB) specimens obtained before NAC were available. As controls, CNB specimens from 42 tumors of the hormone receptor-negative and HER2-positive (HR−/HER2+) subtype and 46 tumors of the hormone receptor-positive and HER2-negative (HR+/HER2−) subtype were also included. Histopathological examination including tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis, and immunohistochemical studies for basal markers were performed, and the correlation of these data with pathological therapeutic effect was analyzed. The rates of pCR at the primary site were higher for TNBC (32%) and the HR−/HER2+ subtype (21%) than for the HR+/HER2− subtype (7%) (P = 0.006). Expression of basal markers and p53, histological grade 3, high TIL scores, and apoptosis were more frequent in TNBC and the HR−/HER2+ subtype than in the HR+/HER2− subtype (P = 0.002 for TIL and P < 0.001 for others). In TNBC, the pCR rates of tumors showing a high TIL score and of those showing a high apoptosis score were 37 and 47%, respectively, and significantly higher or tended to be higher than those of the tumors showing a low TIL score and of the tumors showing a low apoptosis score (16 and 27%, respectively, P = 0.05 and 0.10). In a total of 180 breast cancers, the pCR rates of the tumors showing a high TIL score (34%) and of those showing a high apoptosis score (35%) were significantly higher than those of the tumors showing a low TIL score (10%) and those of the tumors showing a low apoptosis score (19%) (P = 0.0001 and 0.04, respectively). Histological grade and basal marker expression were not correlated with pCR. Although the whole analysis was exploratory, the degree of TIL correlated with immune response appear to play a substantial role in the response to NAC in TNBC.
引用
收藏
页码:793 / 805
页数:12
相关论文
共 50 条
  • [31] Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
    Luen, S. J.
    Salgado, R.
    Dieci, M. V.
    Vingiani, A.
    Curigliano, G.
    Gould, R. E.
    Castaneda, C.
    D'Alfonso, T.
    Sanchez, J.
    Cheng, E.
    Andreopoulou, E.
    Castillo, M.
    Adams, S.
    Demaria, S.
    Symmans, W. F.
    Michiels, S.
    Loi, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (02) : 236 - 242
  • [32] Tumor infiltrating lymphocytes profile and response in neoadjuvant chemotherapy-treated triple-negative breast carcinoma patients
    Ray, Debadrita
    Das Gupta, Senjuti
    De, Arka
    Jain, Parul
    Bhattacharya, Nirmal Kumar
    Biswas, Pranab Kumar
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (06) : 1782 - +
  • [33] Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
    da Silva, Jesse Lopes
    de Albuquerque, Lucas Zanetti
    Rodrigues, Fabiana Resende
    de Mesquita, Guilherme Gomes
    Fernandes, Priscila Valverde
    Thuler, Luiz Claudio Santos
    de Melo, Andreia Cristina
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [34] Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer
    Pruneri, G.
    Vingiani, A.
    Bagnardi, V.
    Rotmensz, N.
    De Rose, A.
    Palazzo, A.
    Colleoni, A. M.
    Goldhirsch, A.
    Viale, G.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (02) : 249 - 256
  • [35] Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy
    Pinard, Clemence
    Debled, Marc
    Ben Rejeb, Houda
    Velasco, Valerie
    Tunon de Lara, Christine
    Hoppe, Stephanie
    Richard, Elodie
    Brouste, Veronique
    Bonnefoi, Herve
    MacGrogan, Gaetan
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (01) : 11 - 23
  • [36] Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy
    Clémence Pinard
    Marc Debled
    Houda Ben Rejeb
    Valérie Velasco
    Christine Tunon de Lara
    Stéphanie Hoppe
    Elodie Richard
    Véronique Brouste
    Hervé Bonnefoi
    Gaëtan MacGrogan
    [J]. Breast Cancer Research and Treatment, 2020, 179 : 11 - 23
  • [37] Relationship between androgen receptor and tumor-infiltrating lymphocytes in triple-negative breast cancer
    Sanchez-Cousido, L. F.
    Lopez-Gonzalez, A.
    Honrado Franco, E.
    Vallejo Pascual, E.
    Sanz, O.
    Lopez Gonzalez, L.
    Delgado, I.
    Lopez-Flores, M.
    Garcia Palomo, A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 80 - 80
  • [38] Comprehensive analysis of variation of tumor infiltrating lymphocytes during neoadjuvant chemotherapy in triple-negative breast cancer.
    Castaneda Altamirano, Carlos
    Ann Mittendorf, Elizabeth
    Arboleda Ezcurra, Patricia
    Casavilca Zambrano, Sandro
    Nunez Butron, Maria Teresa
    Wu, Yun
    Castillo Garcia, Miluska
    Ingrid Rojas, Katerin
    Villegas Bernaola, Valeria
    Belmar Lopez, Carolina
    Dolores Cerna, Ketty
    Leonidas Gomez, Henry
    Abugattas Saba, Julio E.
    Cotrina, Jose M.
    Maria Gonzalez-Angulo, Ana
    Vidaurre, Tatiana
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: A Biomarker for Use Beyond Prognosis?
    Tsoutsou, Pelagia G.
    Bourhis, Jean
    Coukos, George
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (11) : 1297 - +
  • [40] Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response in triple-negative breast cancer: A systematic review and meta-analysis
    Sun, Hai-Kuan
    Jiang, Wen-Long
    Zhang, Shi-Lei
    Xu, Peng-Cheng
    Wei, Li-Min
    Liu, Jiang-Bo
    [J]. WORLD JOURNAL OF CLINICAL ONCOLOGY, 2024, 15 (07):